MDL-206

N/A

Report date: 2025/08/29 17:06:00

Base Information

Drug NameMDL-206
Drug Alias NameMDL 206MDL-206
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionUbiquitin-like modifier-activating enzyme 3A stimulants
TargetsUbiquitin-like modifier-activating enzyme 3A
Therapy Area/IndicationsAngelman SyndromeCentral Nervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesModalis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesModalis Therapeutics CorpModalis Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAngelman SyndromeCentral Nervous System Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A